Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CymaBay Therapeutics, Inc. (CBAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1000+0.2000 (+10.53%)
At close: 04:00PM EDT
2.2500 +0.15 (+7.14%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close1.9000
Open2.0000
Bid2.0400 x 4000
Ask2.2200 x 800
Day's Range1.9200 - 2.1200
52 Week Range1.6700 - 5.0600
Volume811,950
Avg. Volume518,969
Market Cap177.824M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-1.3230
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CBAY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CymaBay Therapeutics Inc.
    Daily – Vickers Top Buyers & Sellers for 01/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Motley Fool

    CymaBay Therapeutics Inc. (CBAY) Q1 2022 Earnings Call Transcript

    Joining me on the call today are Sujal Shah, chief executive officer, and Dan Menold, VP, finance. Following our prepared remarks, we will open the call for Q&A. Before we begin, I'd like to remind everyone that statements made during this conference call, including the Q&A session relating to CymaBay's expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals, funding and repayment schedules, anticipated timelines and trial enrollment dates, cash runway and planning for commercialization are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors.

  • GlobeNewswire

    CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial Results from a 52-week, open-label phase 2 study of seladelpar in patients with PBC published in the Journal of Hepatology Biopharma leader, Éric Lefebvre, M.D. appointed to the Board of Directors Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and

  • GlobeNewswire

    CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022

    Seladelpar Phase 2 Study Selected for DDW Presidential Plenary SessionNEWARK, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple Phase 2 and Phase 3 study presentations on seladelpar, the first delpar currently in development for the treatment of PBC, will be delivered during Digestive Dis

Advertisement
Advertisement